Abstract 2749
Background
Optimal sequencing of new androgen-receptor targeted agents (ART) abiraterone and enzalutamide with docetaxel (D) and cabazitaxel (C) is unknown. In this large retrospective cohort of mCRPC patients, we evaluated the impact of 3 different sequences: D -> C-> ART (group 1), or D -> ART -> C (group 2), or ART -> D -> C (group 3)
Methods
Records of 560 consecutive mCRPC patients were retrospectively collected in 31 centres in 7 European countries from Jan 2011 to Jan 2016. Disease history and clinical characteristics at initiation of each therapy were collected. PSA response ≥ 50%, radiological or clinical progression-free survival (PFS) and overall survival (OS) with each treatment sequence were evaluated.
Results
At sequence initiation, patient characteristics were similar between the 3 sequences: median age was 67 years, 95% were ECOG 0-1, 59% had high disease volume, 42.6% had pain and 8% had visceral metastases. Median number of D cycles was 6 in the 3 groups. Median numbers of C cycles were 7, 6 and 5 in groups 1, 2 and 3 respectively. Median duration of follow-up was 33.7, 31.1, and 23.7 months in groups 1, 2 and 3. Main results are provided in the table.
| Sequence | PSA response ≥50% / Radiological or clinical PFS* | OS from Treatment 1* | ||
|---|---|---|---|---|
| Treatment 1 | Treatment 2 | Treatment 3 | ||
| D- > C- > ART (n = 129) | 61% / 11.5 | 61% / 11.0 | 37% / 12.4 | 37.3 [32.4; 45.2] |
| D- > ART- > C (n = 390) | 63% / 11.9 | 39% / 9.0 | 38% / 11.3 | 36.0 [33.4; 39.7] |
| ART- > D- > C (n = 41) | 60% / 7.4 | 42% / 6.9 | 31% / 8.9 | 30.1 [24.3; 52.7] |
| p value | 0.92 / ConclusionsPSA responses were generally similar for each treatment line in the 3 groups. No significant difference in OS was observed between the 3 sequences in this retrospective cohort. D showed a longer radiological or clinical PFS when given in first line. The activity of C was not influenced by ART. Sequencing should be based on individual disease characteristics and patients' status and preference. Clinical trial identificationLegal entity responsible for the studySponsor ARTIC FundingSanofi and Janssen DisclosureA. Angelergues: Consulting fee Sanofi Travel for meeting Astellas and Janssen. O. Caffo: Speakers bureaus: Astellas, Janssen, Sanofi, Bayer. S. Le Moulec: Nonremunerative positions of influence (eg, officer, board member, trustee, or public spokesperson): Sanofi, Roche, BMS, Merck. A. Guillot: Board Pfizer. D. Spaeth: Consulting fees (or other payment): Sanofi and Janssen. P. Beuzeboc: Consulting fees (or pther payment): Sanofi, Astellas, Janssen, Bayer, Amgen. J-C. Eymard: Consulting fees : Sanofi, Novartis, Pfizer, Janssen Astellas. A. Flechon: Consulting fees (or other payment): Sanofi, Astellas, Ipsen, Janssen, Ferring, Bayer. J. Alexandre: Consulting fees (or other payment): Roche, Pharmamar, Novartis. S. Oudard: Consulting fees (or other payment): Sanofi, Bayer, Astellas, Janssen. All other authors have declared no conflicts of interest. Resources from the same session2354 - The clinicopathologic features and treatment of 607 hindgut neuroendocrine tumor (NET) patients at a single institutionPresenter: Seung Tae Kim Session: Poster Display Resources: Abstract 2594 - Neuroendocrine carcinomas of the colorectal origin - Polish experiencePresenter: Agnieszka Kolasińska-Ćwikła Session: Poster Display Resources: Abstract 2539 - Neuroendocrine neoplasms of the appendix including goblet cell carcinoidsPresenter: Agnieszka Kolasinska-Cwikla Session: Poster Display Resources: Abstract 1245 - Prognostic validity of AJCC staging system in neuroendocrine tumors of the appendixPresenter: Amir Mehrvarz Sarshekeh Session: Poster Display Resources: Abstract 3902 - Enhancer of zest homolog 2 (EZH2) expression in well and moderately differentiated pancreatic neuroendocrine tumor (pNET)Presenter: Riccardo Marconcini Session: Poster Display Resources: Abstract 3882 - Differential clinical and pathological characteristics of hereditary neuroendocrine pancreatic tumours (NEPT)Presenter: Gema Marín Zafra Session: Poster Display Resources: Abstract 2296 - Natural course of thyroid cancer nodules compared with benign thyroid nodulesPresenter: Kyung-Jin Yun Session: Poster Display Resources: Abstract 4083 - Reassessment of proliferative activity at disease progression in neuroendocrine neoplasmsPresenter: Noemi Cicchese Session: Poster Display Resources: Abstract 3866 - 18F-FDG-PET to predict disease progression in advanced digestive neuroendocrine neoplasmsPresenter: Maria Rinzivillo Session: Poster Display Resources: Abstract 3651 - UK phase IV, observational study to assess quality of life in patients (pts) with pancreatic neuroendocrine tumours (pNETS) receiving treatment with everolimus: The “real-world” OBLIQUE studyPresenter: John Ramage Session: Poster Display Resources: Abstract This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
| |||